Wenting Zhang

Dr. Wenting Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WZWenting Zhang
Wenting Zhang
ZXZiqi Xu
Ziqi Xu
YSYamin Shu
Yamin Shu
SSSainan Shu
Sainan Shu
QZQilin Zhang
Qilin Zhang
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages. Due to genetic differences between children and adults in terms of physiology and immunity, there is a need to explore the safety of adalimumab in children in the real world. The aim of this study is to identify potential adverse event (AE) signals associated with the use of adalimumab in pediatric patients (<18 years old) using data from the FDA Adverse Event Reporting System (FAERS). Methods: AEs associated with adalimumab in pediatric patients reported in the FAERS database from the first quarter (Q1) of 2017 to the third quarter (Q3) of 2022 were systematically gathered. Reporting odds ratio (ROR), the proportional reporting ratio (PRR), the information component (IC), and the empirical Bayes geometric mean (EBGM) were used to assess the relationship between adalimumab and AEs in children. Results: Out of 8,363,304 reports collected from the FAERS database during the study period, 3819 reports on children on adalimumab were identified. Adalimumab-related AEs reports were concentrated on 10 toxicity areas and a total of 202 positive signals were detected, of which injection site papule (ROR = 261.97) and intestinal fistula (ROR = 122.09) had the strongest signals. Unexpected significant AEs, including intestinal obstruction, immunodeficiency, abdominal abscess, and Takayasu’s arteritis might also occur. In comparison with patients of all ages in the same time window, the median onset time of children was shorter (99 vs. 149 days). Most of the AE cases occurred in children within the first 1 (1.71%), 2 (8.12%), and 3 months (8.39%) and had early failure types after adalimumab initiation. Methotrexate, folic acid, prednisone, azathioprine, and mesalamine were the top five drugs used concomitantly for adalimumab-associated AEs. Conclusions: When adalimumab is used in children, especially in the first 3 months of treatment, in addition to the AEs recorded in the drug package insert, close attention should be paid to the new potential AEs off-label to ensure the safety of adalimumab in children.

9 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XPXianglin Pan
Xianglin Pan
XXXiangtian Xiao
Xiangtian Xiao
YDYiling Ding
Yiling Ding
YSYamin Shu
Yamin Shu
WZWenting Zhang
Wenting Zhang
LHLiu Huang
Liu Huang
Objective: This study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS) database and to provide reference for safe clinical drug use.Methods: The adverse events report data of oxaliplatin from the first quarter of 2019 (1 January 2019) to the third quarter of 2023 (30 September 2023) were extracted from FAERS database, and the adverse events signal intensity was determined using the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayes geometric mean methods. Time-to-onset and univariate logistic regression analysis were performed to describe the characteristics and risk factors of oxaliplatin-associated neurological adverse events.Results: A total of 4,471 cases of oxaliplatin-associated neurological adverse events were identified, with 318 neurological adverse events being documented, among which 87 adverse events satisfied the thresholds of four methodologies. The median time-to-onset of oxaliplatin-associated neurological adverse events was 2 days (interquartile range 0–36 days). Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.Conclusion: The real-world neurotoxicity spectrum of oxaliplatin and its characteristics and influencing factors were obtained through data mining of FAERS, providing valuable insights for healthcare professionals to effectively manage the risk of neurological adverse events associated with oxaliplatin in clinical practice.

24 February 2026 in Value in Health
Verified
Journal Article
Closed access
YSYamin Shu
Yamin Shu
YTYing Tang
Ying Tang
YDYiling Ding
Yiling Ding
WZWenting Zhang
Wenting Zhang
QZQilin Zhang
Qilin Zhang

11 July 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
XYXueping Yang
Xueping Yang
TWTao Wang
Tao Wang
BZBohua Zhang
Bohua Zhang
WZWenting Zhang
Wenting Zhang
GWGuangjie Wu
Guangjie Wu
YHYan He
Yan He
Object: Colistin sulfate for injection (CSI) became clinically available in China in July 2019. To date, there is no published data regarding its usage in children. Our research group has been following data on the efficacy and safety of CSI in Chinese pediatric patients with carbapenem-resistant organism (CRO) infections. The purpose of this short communication is to provide a brief overview of the findings to date. Methods: We reviewed the electronic medical records of pediatric patients (aged 9-17 years) who were administered CSI during their hospital stay at Tongji Hospital in Wuhan, China, between June 2021 and November 2023. Drug efficacy was evaluated based on clinical and microbiological outcomes, while drug safety was assessed using surveillance markers that reflect adverse reactions. Results: A total of 20 patients met the inclusion criteria. The predominant pathogens were Klebsiella pneumoniae (8 strains), followed by Acinetobacter baumannii (5 strains) and Pseudomonas aeruginosa (2 strains). The clinical response rate of CSI was 85%, with a bacterial clearance rate of 79%. None of the patients experienced colistin-related nephrotoxicity or neurotoxicity during the treatment. Conclusion: In this real-world setting, CSI demonstrated a high level of clinical response and was well tolerated for the treatment of CRO infections in Chinese children.

5 December 2025 in Clinical Case Reports
Verified
Journal Article
Open access
ZXZiqi Xu
Ziqi Xu
WPWen Pan
Wen Pan
HLHui Lei
Hui Lei
CDChen Dong
Chen Dong
BZBiao Zou
Biao Zou
WZWenting Zhang
Wenting Zhang
Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established. This case report presents a 4‐year‐old girl with a mixed infection of CAP who exhibited hypersensitivity to multiple antimicrobial agents (piperacillin‐tazobactam, ceftazidime, fosfomycin, meropenem, and levofloxacin), was treated with omadacycline followed by doxycycline, and underwent bronchoscopy with bronchoalveolar lavage. The child's condition improved, and no adverse reactions to omadacycline were observed. Potential adverse effects of omadacycline were evaluated, along with its utilization and dosage in children. Omadacycline has the potential to be a viable alternative anti‐infective agent for the treatment of pediatric CAP in the absence of other drug options and with adequate safety evaluation and monitoring.

20 April 2026 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
WLWenqi Liu
Wenqi Liu
MCMinyu Chen
Minyu Chen
SWSisi Wang
Sisi Wang
SKShiwen Kang
Shiwen Kang
NZNi Zheng
Ni Zheng
XYXinzhou Yang
Xinzhou Yang